NASDAQ:NCNA NuCana Q3 2024 Earnings Report $1.09 -0.08 (-6.50%) As of 02:35 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast NuCana EPS ResultsActual EPS-$456.00Consensus EPS -$698.00Beat/MissBeat by +$242.00One Year Ago EPSN/ANuCana Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANuCana Announcement DetailsQuarterQ3 2024Date11/25/2024TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsNuCana's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile NuCana Earnings HeadlinesNuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in EuropeSeptember 30 at 8:00 AM | globenewswire.comNuCana Files Q2 2026 Results and Updates U.S. Registration StatementsAugust 16, 2026 | theglobeandmail.comThe rich already moved their moneyBy the time a crash hits the news, it's already too late to protect your money. Parkview Capital's free Market Crash Survival Guide breaks down the specific warning signs flashing in the economy right now the same signals that preceded 2008, 2000, and other downturns that caught unprepared investors off guard. You don't need a financial advisor just ten minutes to see what the data is showing.October 2 at 1:00 AM | Parkview Capital Group (Ad)NuCana Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 13, 2026 | globenewswire.comNuCana plc Sponsored ADRJune 16, 2026 | edition.cnn.comNuCana Appoints Ian Webster as Chief Financial OfficerJune 1, 2026 | globenewswire.comSee More NuCana Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email. Email Address About NuCanaNuCana (NASDAQ:NCNA) plc is a clinical-stage biopharmaceutical company focused on developing cancer treatments designed to improve the delivery and activity of nucleoside analog medicines. The company’s proprietary ProTide technology is intended to help overcome biological barriers that can limit the effectiveness of conventional nucleoside-based therapies. NuCana’s lead investigational product, NUC-3373, is a ProTide-based therapy derived from 5-fluorouracil (5-FU), a commonly used chemotherapy agent. The company has evaluated NUC-3373 in clinical studies involving patients with advanced solid tumors, including colorectal cancer. NuCana has also developed NUC-7738, an investigational ProTide compound derived from the nucleoside analog 3'-deoxyadenosine, for potential use in oncology and immuno-oncology applications. NuCana was founded in the United Kingdom and has conducted research and clinical development activities through international collaborations and studies. The company has been led by Chief Executive Officer Hugh Griffith, one of its founders. Its development programs remain focused on advancing novel cancer therapies through clinical testing and potential regulatory approval.View NuCana ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market ShareCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
